Comparable Outcomes of Matched-Related and Alternative Donor Stem Cell Transplantation for Pediatric Severe Aplastic Anemia  by Kennedy-Nasser, Alana A. et al.
C
A
f
I
m
t
a
e
M
p
U
s
t
e
f
Biology of Blood and Marrow Transplantation 12:1277-1284 (2006)
 2006 American Society for Blood and Marrow Transplantation
1083-8791/06/1212-0001$32.00/0
doi:10.1016/j.bbmt.2006.07.011omparable Outcomes of Matched-Related and
lternative Donor Stem Cell Transplantation
or Pediatric Severe Aplastic Anemia
Alana A. Kennedy-Nasser, Kathryn S. Leung, Anita Mahajan, Heidi L. Weiss, James A. Arce,
Stephen Gottschalk, George Carrum, Shakila P. Khan, Helen E. Heslop, Malcolm K. Brenner,
Catherine M. Bollard, Robert A. Krance
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children’s
Hospital, Houston, Texas
Correspondence and reprint requests: Alana A. Kennedy-Nasser, MD, Center for Cell and Gene Therapy, Baylor
College of Medicine, The Methodist Hospital and Texas Children’s Hospital, Houston, TX 77030 (e-mail:
aakenned@txccc.org).
Received May 5, 2006; accepted July 20, 2006
ABSTRACT
Matched sibling donor (MSD) bone marrow transplantation is the treatment of choice for pediatric patients
with severe aplastic anemia (SAA); however, only about 33% of patients will have an HLA-identical sibling.
Alternative donor (AD) transplants may be an option for these patients, but such therapies have been associated
with greater incidence of graft failure and graft-versus-host disease (GVHD). We retrospectively analyzed 36
pediatric patients who received 38 bone marrow or peripheral blood stem cell transplants (15 MSD and 23 AD)
for SAA at our institution from April 1997 to October 2005. Nineteen AD recipients received reduced intensity
conditioning with cyclophosphamide, low-dose total body irradiation, and antithymocyte globulin (ATG) or
Campath. The 4-year overall survival for MSD recipients was 93% versus 89% for AD recipients treated with
reduced intensity conditioning regimens at a median follow-up of 52 months (range, 6-99 months). No patient
receiving Campath, compared with 3 of 9 patients receiving ATG, developed extensive, chronic GVHD. We
conclude that, for children with SAA, AD transplantation is as effective as MSD transplantation. Further,
compared with ATG, preparatory regimens containing Campath may be associated with a lower incidence of
extensive, chronic GHVD.
© 2006 American Society for Blood and Marrow Transplantation
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ANTRODUCTION
HLA-identical matched sibling donor (MSD) he-
atopoietic stem cell transplantation (HSCT) is the
reatment of choice for pediatric patients with severe
plastic anemia (SAA). Storb et al [1] reported an 88%
vent-free survival for 81 patients with SAA receiving
SD transplantation after conditioning with cyclo-
hosphamide and antithymocyte globulin (ATG).
nfortunately, only about 33% of patients have a
uitably HLA-matched sibling [1-4]. Results from al-
ernative donor (AD) transplantations have been less
ncouraging, mainly because of high rates of graft
ailure and severe graft-versus-host disease (GVHD) S3-5]. Data from the International Bone Marrow
ransplant Registry for 732 pediatric patients who
nderwent transplantation with MSD grafts between
996 and 2001 showed a 3-year survival of 82% but
nly 53% survival for 218 pediatric patients who re-
eived transplants from unrelated donors [6]. The
enter for International Blood and Marrow Trans-
lant Research reported a 30% to 49% 5-year overall
urvival for 318 AD grafts [7]. Thus, the trend has been
o offer immunosuppressive therapy (IST) to pediatric
atients with SAA who do not have anMSD and to offer
D transplants only if immunosuppression fails.
Although survival rates after IST in children with
AA have been reported to be as high as 80% [8,9],
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A. A. Kennedy-Nasser et al.1278reatment failure occurs in 40% to 50% of cases [10].
urther, late clonal complications including myelo-
ysplasia and paroxysmal nocturnal hemoglobinuria
ay develop in 25% to 45% of patients undergoing
ST by 7 to 11 years after therapy [11-14].
Reports for patients who underwent AD trans-
lantation by European groups and the National Mar-
ow Donor Program suggest that high-dose total body
rradiation (TBI) regimens, although effective in
chieving engraftment, also increase toxicity, so that
urvival is not improved [15-18]. Deeg et al [19] re-
orted the results of a multicenter, prospective, phase
study in which the minimum effective dose of TBI
as determined in patients with SAA undergoing un-
elated donor HSCT. They concluded that a TBI
ose of 200 cGy in combination with cyclophospha-
ide and ATG was sufﬁcient for engraftment in
atched unrelated donor (MUD) grafts without in-
urring unacceptable toxicities.
At our institution, all patients with SAA and
atched siblings receive HSCT. Other patients ini-
ially receive IST and, if this fails, they receive AD
ransplants. We report that MSD and AD HSCT
sing reduced intensity conditioning regimens have
ssentially identical outcomes in pediatric patients
ith SAA.
ETHODS
atients
Between April 1997 and October 2005, 36 con-
ecutive pediatric patients with SAA underwent allo-
eneic HSCT at Texas Children’s Hospital (n  35)
nd The Methodist Hospital (n  1) in studies ap-
roved by the institutional review boards. SAA was
eﬁned as any 2 of the following: neutrophil count
0.5  109/L, platelet count 20  109/L, or reticu-
ocytes 1% and marrow features of severe hypocel-
ularity or moderate hypocellularity (35% cellular-
ty) [20]. All patients had acquired SAA (Table 1).
anconi anemia was excluded in all patients by using
hromosomal breakage studies.
The median age at time of transplantation was 9.4
ears (range, 1.3-18.4 years; 20 boys and 16 girls).
edian times from diagnosis to transplantation were
.8 months for all patients (range, 1.2-51.6 months),
.4 months for MSD recipients, and 6 months for AD
ecipients. This difference reﬂects that all but 1 of the
D recipients received and failed IST before trans-
lantation.
one Marrow Donor Selection
Donor characteristics for all transplants are listed
n Table 1. Unrelated donors were recruited through
he National Marrow Donor Program. DNA-based
llele typing for class II DR has been performed since t997. Class I A and B typing was antigen speciﬁc until
arch 2005, when allele typing was instituted. The
edian age of ADs was 35 years (range, 23-50 years).
he median age of MSDs was 11 years (range, 0.3-22
ears).
ransplants
Thirty-six consecutive patients with acquired SAA
eceived 38 allogeneic transplants. Fifteen patients
nitially received MSD transplants and 21 received AD
ransplants: 11 MUD, 7 mismatched unrelated donor
MMUD), and 3 mismatched related donor. Two of
hese 36 patients received a second transplant: 1 MSD
ecipient had late graft failures despite several addi-
ional donor cell infusions and 8 years later received a
UD graft after reduced intensity conditioning (for
he purpose of statistical analysis, this patient was
ensored at the time of undergoing MUD transplan-
ation). One patient had a failed engraftment after
MUD transplantation at 17 years of age, and 2
onths later received a peripheral blood stem cell
able 1. Patient and Donor Characteristics
atients, n 36
ransplants, n* 38
ge (y), median (range) 9.4 (1.3-18.4)
emale/male, n 16/20
ossible causes of acquired aplastic anemia, n
Idiopathic 33
Hepatitis 1
Paroxysmal nocturnal hemoglobinuria 2
rior treatment, n
Antithymocyte globulin 13
Cyclosporine 15
Steroids 15
Granulocyte colony-stimulating factors 7
ime from diagnosis to transplantation (mo),
median (range) 4.8 (1.2-51.6)
Matched sibling donor recipients 2.4
Alternative donor recipients 6.0
ype of transplant, n
Matched sibling donor 15
Alternative donor 23
Matched unrelated donor 12
Mismatched unrelated donor 7
Mismatched related donor 3
Haploidentical 1
D34 cell dose (106)/kg, median (range) 3.7 (0.2-13.7)
atched sibling donors, n 15
Age (y), median (range) 11 (0.3-22)
Female/male, n 6/9
lternative donors, n 23
Age (y), median (range) 35 (23-50)
Female/male, n 10/13
Two patients received second transplants (1 matched sibling donor
recipient later received a matched unrelated donor graft and 1
mismatched unrelated donor recipient later received a hap-
loidentical graft).ransplant from a haploidentical parent.
Sm
(
m
l
s
o
f
C
T
p
e
t
M
b
a
a
T
i
p
l
c
P
2
d
h
C
d
1
d
m
c
o
a
p
f
I
r
G
o
p
i
r
M
o
S
c
S
t
i
t
a
e
R
a
E
n
p
p
(
i
w
o
t
1
w
g
u
s
d
C
m
p
a
q
(
c
o
p
i
a
c
S
d
o
a
w
r
f
t
t
1
Comparable Outcomes of MSD and AD HSCT for Pediatric SAA 1279tem Cell Products
The source of stem cells was unmanipulated bone
arrow (n  34) or CD34-selected peripheral blood
Isolex [Baxter, Irvine, California]; n  4; 1 mis-
atched related donor, 1 MUD, 1 MSD, and 1 hap-
oidentical graft) collected after granulocyte colony-
timulating factor mobilization. For marrow a median
f 4.97 total nucleated cells/kg (range, 0.79-34.94) and
or CD34-selected products a median of 8.02
D34/kg (range, 6.53-10.10) were infused.
ransplantation Protocol for MSD HSCT
Fourteen of 15 MSD recipients received cyclo-
hosphamide 50 mg/kg for 4 days (days5 to2) and
quine ATG (ATGAM) 30 mg/kg for 3 days (days 5
o 3) in accord with the Seattle regimen [1]. One
SD recipient with paroxysmal nocturnal hemoglo-
inuria received busulfan for 4 days (days 7 to 4)
nd cyclophosphamide 50 mg/kg for 2 days (days 3
nd 2).
ransplantation Protocol for AD HSCT
Nineteen of 23 AD recipients received a reduced
ntensity conditioning regimen consisting of cyclo-
hosphamide 50 mg/kg for 4 days (days6 to3) and
ow-dose TBI (200 cGy for MUD on day 2 and 200
Gy for MMUD recipients on days 2 and 1).
atients who underwent transplantation from 1997 to
000 received equine ATG (ATGAM) 30 mg/kg for 3
ays (days 5 to 3). After 2000, patients received
umanized anti-CD52 monoclonal antibodies and
ampath-1H (alemtuzumab) in a weight-dependent
ose (3 mg for patients 5-15 kg, 5 mg for patients
6-30 kg, and 10 mg for patients 30 kg) daily for 4
ays (days 4 to 1). Three patients received fully
yeloablative preparative regimens and 1 patient re-
eived a subablative regimen of ﬂudarabine 30 mg/m2
n days5 to2, Campath 10 mg on days5 to2,
nd low-dose TBI conditioning for a haploidentical
eripheral blood stem cell transplant 2 months after
ailing to engraft from an initial MMUD transplant.
n all, 9 AD grafts included ATG in the preparative
egimen and 14 included Campath.
VHD and Infectious Prophylaxis
All patients received FK506 or cyclosporine, with
r without methotrexate for GVHD prophylaxis. All
atients received bacterial and fungal prophylaxis dur-
ng the peri-transplantation period and all patients
eceived pneumocystis carinii pneumonia prophylaxis.
onitoring of viral and fungal infections was carried
ut as per institutional standard of care [21].
tatistical Methods
Engraftment rates and incidences of acute and
hronic GVHD are reported for each patient group. turvival time was calculated from date of transplanta-
ion to date of death or date of ﬁnal patient follow-up
n March 2006. Kaplan-Meier survival curves and es-
imates of survival rates at speciﬁc time points in
ddition to 95% conﬁdence intervals are estimated for
ach group of patients.
ESULTS
Tables 2 and 3 list the transplant characteristics
nd outcomes of MSD and AD recipients.
ngraftment
Engraftment was deﬁned as a sustained (3-day)
eutrophil count 0.5  109/L and unsupported
latelet count20 109/L. Thirty-seven of 38 trans-
lants were evaluable for engraftment. One patient
no. 11) died of a pre-existing Pseudomonas aeruginosa
nfection only 6 days after MSD transplantation and
as therefore unevaluable for engraftment. Thirty-six
f 37 (97%) evaluable transplants engrafted. Median
ime to neutrophil engraftment was 17 days (range,
1-44 days) and median time to platelet engraftment
as 32 days (range, 11-282 days). One patient’s en-
raftment failed (no. 34) after MMUD transplantation
sing reduced intensity conditioning but was later
uccessful after haploidentical transplantation using a
ifferent reduced intensity conditioning regimen.
himerism Studies
Chimerism was determined on blood and/or bone
arrow using ﬂuorescence in situ hybridization
robes for sex chromosomes or polymerase chain re-
ction ampliﬁcation of speciﬁc polymorphic DNA se-
uences (short tandem repeats). Thirty-four of 36
94%) evaluable transplant patients had 95% donor
himerism. Seven of 14 (50%) MSD recipients and 17
f 22 (77%) AD recipients were 100% chimeric. One
atient had autologous recovery (MSD recipient) and
s transfusion independent with 100% recipient cells
nd 50%-70% bone marrow cellularity with normal
ytogenetics.
urvival
Thirty-one of 36 (86.1%) patients have survived to
ate as transfusion independent, at a median follow-up
f 52 months (range, 6-99 months). The 4-year over-
ll survival was 93% in the MSD group compared
ith 89% in the AD group of patients receiving this
educed intensity regimen. There was no statistical dif-
erence between these 2 groups of patients (Figure 1).
Five patients died at a median of 52 days after
ransplantation (range, 6 days to 5.5 years). Four pa-
ients died of infection soon after transplantation and
patient (no. 16) died 5.5 years after MUD transplan-
ation from chronic GVHD pulmonary complications
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A. A. Kennedy-Nasser et al.1280esulting in pulmonary failure (Table 4). For patients
ying from infection, the causes of death were pre-
xisting pseudomonas (n  2), idiopathic pneumonia
n  1), and adenovirus complicated by acute GVHD
n  1).
Ten patients (3 MSD, 7 AD) developed cytomeg-
lovirus (CMV) reactivation without CMV disease.
ive patients received ATG or Campath in the con-
itioning regimen, and frequencies of CMV infection
ere 36% with Campath and 23% with ATG. Two of
hese patients died; 1 MUD recipient who received
TG as a result of pre-existing pseudomonas infection
nd 1 MUD recipient who received Campath died
rom adenoviral infection. An additional patient who
eceived Campath developed Epstein-Barr viral reac-
ivation, which was treated successfully with ritux-
mab.
raft-versus-Host Disease
Severe, acute GVHD (grade III or IV) developed
n 0 of 15 MSD recipients and 4 of 23 AD recipients.
peciﬁcally, 2 of 9 AD recipients who received ATG
eveloped severe, acute GVHD compared with 2 of
4 Campath recipients. Extensive, chronic GVHD
eveloped in 0 of 15 MSD recipients and 3 of 23 AD
ecipients, all 3 of whom received ATG in the pre-
arative regimen. No patient treated with Campath
eveloped extensive, chronic GVHD. One MMUD
ecipient (no. 23) with hepatitis-associated SAA devel-
ped grade IV acute GVHD and extensive, chronic
VHD of the liver, received a liver transplant, and is
ow well and disease free.
ISCUSSION
Although the outcomes after MSD transplantation
or pediatric SAA have improved over the years, the
esults using AD transplants have been less satisfac-
ory. Margolis and Casper [5] reported 55% survival
t 33 months for 28 heavily transfused adult and pe-
iatric patients with SAA undergoing AD HSCT us-
ng an intensive conditioning regimen. Because of
hese and similar results [3-7], immunosuppression
as remained ﬁrst-line therapy for patients lacking
n HLA-matched sibling. Unfortunately, IST has
chieved limited improvement in survival, with high
ates of clonal evolution and relapse [8,11-13,22,23].
n addition, delayed time to transplantation presum-
bly due to IST administration has been associated
ith a poorer outcome in several studies [7,24]. This
as led to the use of nonmyeloablative or reduced
ntensity preparative regimens to improve survival for
ecipients of AD transplants. The European Group
or Blood and Marrow Transplantation Working
arty reported 73% survival for 38 adult and pediatricpatients when using a reduced intensity conditioningTa Pa N
A
*P
a
Table 3. Transplant Characteristics and Outcomes in Alternative Donor Recipients
Patient
No.
D/R Age (y)
Sex
Type of
HSCT
HLA Matched,
Mismatched Ag
Time to
HSCT (mo)
Conditioning
Regimen
ATG or
Campath
Acute
GVHD
Chronic
GVHD
CMV or EBV
Reactivation Disease Status Chimerism Studies
16 23F/9F MUD 6/6 34.8 Cy, TBI ATG Grade 3 Ext No Died 100% donor RFLP
17 ?M/3M MUD 6/6 12 AraC, Cy, TBI ATG No No No Died NA
18 35F/1F MUD 6/6 4.8 Cy, TBI ATG No No No Alive 100% donor STR
19 30F/1M MMRD 5/6, B 4.8 AraC, Cy, TBI ATG No No No Alive 100 of 100 donor FISH
20 30M/5F MMUD 5/6, DRBI 21.6 AraC, Cy, TBI ATG No No No Alive 100% donor STR
21 37M/6M MMUD 5/6, DRBI 4.8 Cy, TBI ATG No No No Alive 100% donor STR
22 28M/16M MMUD 5/6, B 22.8 Cy, TBI ATG No No CMV Alive, CMV neg 200 of 200 donor FISH
23 38F/14M MMUD 5/6, DRB1 3.6 Cy, TBI ATG Grade 4 Ext No Alive 199 of 200 donor FISH
24 28F/18F MUD 6/6 22.8 Cy, TBI ATG No Ext CMV Alive, CMV neg 100% donor STR
25 30M/5F MUD 6/6 NA Cy, TBI Campath Grade 4 No CMV Died, CMV neg 200 of 200 donor FISH
26 44F/10M MMRD 5/6, DRB1 6 Cy, TBI Campath No Lim CMV Alive, CMV neg 100% donor STR
27 44M/12F MUD 6/6 16.8 Cy, TBI Campath No No No Alive 100% donor STR
28 24F/6M MUD 6/6 12 Cy, TBI Campath No No CMV Alive, CMV neg 198 of 200 donor FISH
29 40F/12M MUD 6/6 2.4 Cy, TBI Campath No No CMV Alive, CMV neg 194 of 200 donor FISH
30 30M/8F MUD 6/6 6 Cy, TBI Campath No No No Alive 200 of 200 donor FISH
31 43F/18F MMRD 5/6, DRB1 24 Cy, TBI Campath No NA No Died 100% donor STR
32 36F/8F MMUD 5/6, DRB1 3.6 Cy, TBI Campath No No CMV Alive, CMV neg 100% donor STR
33 36M/8F MMUD 5/6, B 51.6 Cy, TBI Campath Grade 3 No No Alive 200 of 200 donor FISH
34* 34M/17F MMUD 5/6, A 6 Cy, TBI Campath No No No Failed to engraft NA
35* 50M/17F Haplo 3/6, A, B, DRBI NA Flu, TBI Campath No No CMV Alive, CMV neg 100 of 100 donor FISH
36† 33M/18M MUD 6/6 NA Cy, TBI Campath No No No Alive 100% donor STR
37 24M/14M MUD 8/10, A 9.6 Cy, TBI Campath No No EBV Alive, EBV neg 100% donor STR
38 35M/14M MUD 6/6 40.8 Cy, TBI Campath No No No Alive 100% donor STR
NA indicates not available or applicable; HSCT, hematopoietic stem cell transplantation; GVHD, graft-versus-host disease; CMV, cytomegalovirus; EBV, Epstein-Barr virus; D, donor; R, recipient;
M, male; F, female; HLA, human-leukocyte antigens; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; MMRD, mismatched related donor; Haplo, haploidentical; Cy,
cyclophosphamide; TBI, total body irradiation; AraC, cytarabine arabinoside; Flu, ﬂudarabine; Bu, busulfan; ATG, antithymocyte globulin; Ext, extensive; Lim, limited; RFLP, restriction fragment
length polymorphism; FISH, ﬂuorescence in situ hybridization; STR, short tandem repeats; Ag, antigen.
*Patients 34 and 35 are the same patient.
†Patient 36 is also patient 1 in Table 2.
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A. A. Kennedy-Nasser et al.1282egimen of ﬂudarabine, cyclophosphamide, and ATG
25]. Another study reported 75% survival with dura-
le engraftment using non-TBI preparative regimens
or 13 mostly young adult patients with SAA who
eceived AD transplants [26]. Vassiliou et al [27] re-
orted 100% survival with AD HSCT using Cam-
ath, low-dose TBI, and cyclophosphamide as re-
uced intensity conditioning in 8 patients. In addition,
ow-dose TBI with cyclophosphamide and ATG has
een shown to be effective in securing durable grafts
ith acceptable toxicities in MUD grafts [2].
We ﬁnd that this reduced intensity conditioning
egimen with low-dose TBI achieves stable engraft-
ent and excellent survival. There is concern that
hese patients may be at risk for secondary malignan-
ies but none has occurred up to 86 months after AD
ransplantation. After irradiation, the risk for thyroid
ancer is expected to be highest in children exposed at
n age 5 years [28]. For patients with SAA excluding
anconi anemia undergoing MSD and AD transplan-
ation [29], the estimated risk for developing any ma-
ignancy by 20 years (range, 1.4-221 months) was
eported as 14%. The risk of malignancy likely has a
inear relation to radiation doses up to 7-8 Gy. Al-
hough the risk of malignancy after conditioning reg-
mens that include radiation are of obvious concern,
hese risks may be little different from those incurred
igure 1. Probability of 4-year overall survival for MSD recipients
as 93% versus 89% for AD recipients who received reduced
ntensity conditioning. CI indicates conﬁdence interval.
able 4. Deaths
Patient
No.
Age (y) at Time
of HSCT
Type of
HSCT
Conditioning
Regimen
11 4.0 MSD Cy
16 9.4 MUD RI
17 3.3 MUD Myeloablative
25 18.4 MMRD RI
31 5.9 MUD RI
I indicates reduced intensity; HSCT, hematopoietic stem cell tra
donor; MUD, matched unrelated donor; Cy, cyclophosphamide; GVHfter IST alone or after transplant-preparative regi-
ens that use only chemotherapy. Lifelong follow-up
or all these patients is therefore necessary.
Fludarabine has been used in preparative regimens
ithout TBI. Although a survival of 71% to 84% has
een noted for patients who received AD transplants
25,30-33], this regimen has led to a reportedly higher
ncidence of graft failure and GVHD in some studies
30,32]. Although ﬂudarabine-based conditioning reg-
mens remain promising, the incidence of GVHD
sing our conditioning regimen (especially in the pa-
ients who received Campath) appears lower than that
n other reported series. Certainly, the long-term
20-year) effects of a ﬂudarabine-based or low-dose
BI-based preparatory regimen have yet to be deter-
ined.
Campath was substituted for ATG because it al-
ows for predictable depletion of T and B lymphocytes
34,35]. As previously published by our group and
thers, Campath may be associated with higher rates
f viral infections such as CMV and adenovirus [36-
8]; however, in our patients, there was no CMV
isease.
Previous studies have shown that AD transplants
esult in an increased incidence of graft rejection and
n increased risk of death from acute GVHD, infec-
ion, and pneumonitis when compared with MSD
ransplantation [25]. However, other groups have
oted an association with lower rates of GVHD using
ampath [39,40]. Although graft failure has been an
ngoing concern in patients with SAA undergoing AD
SCT, in our experience only 1 patient’s engraftment
ailed and GVHD was minimal in this cohort of pa-
ients. None of the patients who received Campath
eveloped extensive, chronic GVHD compared with 3
f 9 ATG recipients in the AD group; however, the
ample was too small to determine signiﬁcance.
Many studies have shown that survival after
SCT is improved by shortening the time to trans-
lantation, thereby decreasing blood product expo-
ures and minimizing prior therapy [24,25,41]. In our
eport, the median time to transplantation was notably
onger in the AD than in the MSD group (6 versus 2.4
onths). This delay was attributed to the fact that all
ut 1 of the AD recipients received and failed IST
or
ath
Time of Death
after HSCT Cause of Death
6 d Pre-existing infection
5.5 y Chronic GVHD, pulmonary failure
33 d Pre-existing infection
ath 52 d Idiopathic pneumonia
ath 66 d Adenovirus, grade IV acute GVHD
ation; MSD, matched sibling donor; MMRD, mismatched relatedATG
Camp
ATG
ATG
ATG
Camp
Camp
nsplant
D, graft-versus-host disease; ATG, antithymocyte globulin.
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Comparable Outcomes of MSD and AD HSCT for Pediatric SAA 1283efore transplantation. However, we observed no ef-
ect of time from diagnosis to transplantation on sur-
ival, even though AD transplantation was performed
ater after diagnosis than MSD transplantation. Some
receding IST for these patients may have favored
ubsequent engraftment when low-intensity condi-
ioning was used.
We have shown that a reduced intensity condi-
ioning regimen of cyclophosphamide, low-dose TBI,
nd ATG or Campath achieves sustained engraftment
nd excellent survival in pediatric patients with SAA
ho receive AD transplants. These results are com-
arable to the outcome for pediatric patients with SAA
ho received MSD transplants.
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